NL-OMON21596
Not Yet Recruiting
N/A
A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation
HOVON<br>VU University Medical Center,<br>P.O.Box 7057<br>1007 MB Amsterdam<br>The Netherlands<br>tel: +31 20 4442124<br>tel: +31 20 4449086<br>Fax: +31 20 44435660 sites70 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- HOVON<br>VU University Medical Center,<br>P.O.Box 7057<br>1007 MB Amsterdam<br>The Netherlands<br>tel: +31 20 4442124<br>tel: +31 20 4449086<br>Fax: +31 20 4443566
- Enrollment
- 70
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with a confirmed diagnosis of post\-ET, post\-PV or primary myelofibrosis (Appendix A)
- •\- Intermediate\-2 or high\-risk according to DIPSS plus
- •(Appendix E)
Exclusion Criteria
- •\- Previous treatment with JAK2 inhibitors within 2 weeks
- •of study inclusion. Patients who have been treated with
- •pacritinib as their previous JAK2 inhibitor treatment
- •cannot participate in this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantatioPrimary myelofibrosisPolycythemia veraEssential thrombocytosisMedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-000195-98-NLHOVON Foundation70
Active, Not Recruiting
Phase 1
A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantatioPrimary myelofibrosisPolycythemia veraEssential thrombocytosisMedDRA version: 20.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-000195-98-BEHOVON Foundation70
Recruiting
Phase 2
A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantatioNL-OMON47477HOVO65
Terminated
Phase 2
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With RuxolitinibPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia MyelofibrosisNCT02226172Pfizer21
Completed
Phase 2
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid MetaplasiaEssential ThrombocythemiaPolycythemia VeraPrimary MyelofibrosisNCT00047190National Cancer Institute (NCI)35